Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for IMUX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -31.00M
March 31, 2026 -17.30M
December 31, 2025 -19.28M
September 30, 2025 -20.14M
June 30, 2025 -24.61M
March 31, 2025 -21.78M
December 31, 2024 -22.96M
September 30, 2024 -20.80M
June 30, 2024 -17.03M
March 31, 2024 -23.97M
December 31, 2023 -14.03M
September 30, 2023 -17.31M
June 30, 2023 -19.98M
March 31, 2023 -19.51M
December 31, 2022 -15.10M
September 30, 2022 -13.60M
June 30, 2022 -15.76M
March 31, 2022 -20.68M
December 31, 2021 -23.68M
September 30, 2021 -17.60M
June 30, 2021 -29.00M
March 31, 2021 -12.95M
December 31, 2020 -13.96M
September 30, 2020 -11.90M
June 30, 2020 -9.227M
Date Value
March 31, 2020 -11.03M
December 31, 2019 -6.535M
September 30, 2019 -5.976M
June 30, 2019 -10.99M
March 31, 2019 -5.317M
December 31, 2018 -3.445M
September 30, 2018 -2.085M
June 30, 2018 8.866M
March 31, 2018 -13.07M
December 31, 2017 -9.92M
September 30, 2017 -9.417M
June 30, 2017 -10.15M
March 31, 2017 -10.91M
December 31, 2016 -9.102M
September 30, 2016 -7.889M
June 30, 2016 -8.827M
March 31, 2016 -9.956M
December 31, 2015 -9.291M
September 30, 2015 -12.04M
June 30, 2015 -15.12M
March 31, 2015 -13.51M
December 31, 2014 -10.39M
September 30, 2014 -11.19M
June 30, 2014 -9.878M
March 31, 2014 -9.364M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 100.78M
Sionna Therapeutics, Inc. -22.22M
Alnylam Pharmaceuticals, Inc. 326.72M
Anika Therapeutics, Inc. -0.684M
Savara, Inc. -29.75M